Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.

International urology and nephrology - 1 Sept 2011

Alsaran Khalid, Sabry Alaa, Shaheen Naila

Abstract excerpt

INTRODUCTION: Chronic hepatitis C infection is common among patients on dialysis. While the associated liver disease is usually relatively mild during dialysis, disease progression can accelerate due to immunosuppression following kidney transplantation, and interferon therapy after transplantation stimulates graft rejection. Pegylated interferon and ribavirin are now the recommended treatment for chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alanine Transaminase
Share to Anemia
Share to Aspartate Aminotransferases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hemoglobins

Share to Leukocyte Count

Share to Platelet Count

Share to Renal Dialysis

Share to Saudi Arabia

Source

Identifiers

PMID: 20490669
DOI: 10.1007/s11255-010-9756-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.PMID 20490669Read ↗

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C in dialysis units: the Saudi experience.Semantic proximity Read ↗

Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.Semantic proximity Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.Semantic proximity Read ↗

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety.Semantic proximity Read ↗

KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C.Semantic proximity Read ↗

The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.Semantic proximity Read ↗

Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection.Semantic proximity Read ↗

Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

Efficacy and tolerability of low-dose interferon-α in hemodialysis patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.